Local, national & international business news and events.
Wiley Announces Quarterly Dividend, HOBOKEN, N.J.–(BUSINESS WIRE)–John Wiley and Sons (NYSE:JWA)(NYSE:JWB), a global research and education company, today announced that its Board of Directors has declared a quarterly cash dividend of $0.3425 per share on its Class A and Class B Common
Life sciences commercial organizations can now forecast sales, predict churn, analyze brand propensity and launch new products with BirdzAI PISCATAWAY TOWNSHIP, N.J.–(BUSINESS WIRE)–#AI—P360, a leading developer of technology for life sciences companies, today announced major updates to its sales enablement platform BirdzAI.
Immetas Therapeutics Announces Series A Financing to Advance Research on Inflammation Pathways in Aging and Develop Therapeutics for Cancer and Inflammatory Disease, EAST HANOVER, N.J.–(BUSINESS WIRE)–Immetas Therapeutics today announced it has raised a Series A financing of $11 million to advance research
Billionaire Mike Bloomberg is helping Florida felons pay their debts so they can vote in the presidential election. — ABC News: Top Stories
Frost & Sullivan Names Vonage Asia-Pacific Communications Platform as a Service (CPaaS) Provider of the Year for Second Consecutive Year, HOLMDEL, N.J.–(BUSINESS WIRE)–For the second year in a row, Frost & Sullivan has named Vonage (Nasdaq: VG), a global leader in cloud
Pathline Labs Doubles Testing Capacity for COVID-19, Adds Major Clients Throughout U.S., Testing through Pathline Labs is now available nationwide RAMSEY, N.J.–(BUSINESS WIRE)–Pathline Labs, a leading provider of sub-specialized anatomic pathology, has expanded its COVID-19 testing capabilities across the country while maintaining
LYNPARZA is the Only PARP Inhibitor to Demonstrate Improved Overall Survival in Metastatic Castration-Resistant Prostate Cancer KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced final results from the Phase 3 PROfound
Researchers Share New Data for Vibostolimab (MK-7684), Merck’s Anti-TIGIT Therapy, as Monotherapy and in Combination With KEYTRUDA® (pembrolizumab); First-Time Results for First-in-Class MK-4830 (Anti-ILT4 Therapy); and Late-Breaking Data for MK-6482 (HIF-2α Inhibitor) Merck to Initiate Phase 3 Study of Vibostolimab in Non-Small
The news media landscape has been evolving, where independent bloggers and freelancers are an essential part of the news ecosystem, which supports our democracy. Nevertheless, due to the new digital era and the independent roles that have been established, some bloggers and